process for the review of abbreviated applications for generic new animal drugs
(10)The term “process for the review of abbreviated applications for generic new animal drugs” means the following activities of the Secretary with respect to the review of abbreviated applications, supplemental abbreviated applications, and investigational submissions: (A)The activities necessary for the review of abbreviated applications, supplemental abbreviated applications, and investigational submissions. (B)The issuance of action letters which approve abbreviated applications or supplemental abbreviated applications or which set forth in detail the specific deficiencies in abbreviated applications, supplemental abbreviated applications, or investigational submissions and, where appropriate, the actions necessary to place such applications, supplemental applications, or submissions in condition for approval. (C)The inspection of generic new animal drug establishments and other facilities undertaken as part of the Secretary’s review of pending abbreviated applications, supplemental abbreviated applications, and investigational submissions. (D)Monitoring of research conducted in connection with the review of abbreviated applications, supplemental abbreviated applications, and investigational submissions. (E)The development of regulations and policy related to the review of abbreviated applications, supplemental abbreviated applications, and investigational submissions. (F)Development of standards for products subject to review. (G)Meetings between the agency and the generic new animal drug sponsor. (H)Review of advertising and labeling prior to approval of an abbreviated application or supplemental abbreviated application, but not after such application has been approved.